Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
A Al-Janabi,1,2 ZZN Yiu1,2 1Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK; 2The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research...
Main Authors: | Al-Janabi A, Yiu ZZN |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-01-01
|
Series: | Psoriasis: Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/biologics-in-psoriasis-updated-perspectives-on-long-term-safety-and-ri-peer-reviewed-fulltext-article-PTT |
Similar Items
-
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
by: Al-Janabi A, et al.
Published: (2022-07-01) -
Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis
by: Jose Manuel Dodero-Anillo, et al.
Published: (2022-12-01) -
Adverse reactions to biologics for psoriasis and countermeasures
by: Yang YANG, et al.
Published: (2023-08-01) -
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
by: Potestio L, et al.
Published: (2023-08-01) -
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
by: Potestio L, et al.
Published: (2023-04-01)